Uwe Walter1, Mario Fuchs2, Annette Grossmann3, Michael Walter4, Thomas Thiele5, Alexander Storch2, Matthias Wittstock2. 1. Department of Neurology, Rostock University Medical Center, Rostock, Germany uwe.walter@med.uni-rostock.de. 2. Department of Neurology, Rostock University Medical Center, Rostock, Germany. 3. Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, Rostock University Medical Center, Rostock, Germany. 4. Institute of Clinical Chemistry and Laboratory Medicine, Rostock University Medical Center, Rostock, Germany. 5. Institute of Immunology and Transfusion Medicine, Greifswald University Medical Center, Greifswald, Germany.
Abstract
OBJECTIVE: Venous thromboses and thrombocytopenia after vaccination with the adenovirus-vectored COVID-19 vaccine ChAdOx1 nCov-19 (AstraZeneca) have been linked to serum antibodies against platelet factor 4 (PF4)-polyanion complexes. We here report vaccine-induced isolated carotid arterial thrombosis. METHODS: Imaging and laboratory findings, treatment decisions and outcome of this case are presented. RESULTS: Eight days after having received the first dose of ChAdOx1 nCov-19 vaccine, a 31-year-old man was admitted to our stroke unit with acute headache, aphasia, and hemiparesis. D-dimers were slightly elevated, but platelet count and fibrinogen level were normal. MRI-confirmed mainstem occlusion of middle cerebral artery resolved within 1 hour after start of IV thrombolysis. A wall-adherent, non-occluding thrombus in the ipsilateral carotid bulb was identified as the source of embolism. Cardiac or paradoxical (venous) embolism was excluded. Screening for presence of heparin-induced thrombocytopenia-related antibodies was positive, and highly elevated serum IgG antibodies against PF4-polyanion complexes were subsequently proven. Treatment with aspirin and subcutaneous danaparoid, followed by phenprocoumon, led to thrombus shrinkage and dissolution within 19 days, and favorable clinical outcome. DISCUSSION: Vaccine history is important in patients not only with venous but also with arterial thromboembolic events. Vaccine-induced immune thrombosis of brain-supplying arteries may well be handled.
OBJECTIVE:Venous thromboses and thrombocytopenia after vaccination with the adenovirus-vectored COVID-19 vaccine ChAdOx1 nCov-19 (AstraZeneca) have been linked to serum antibodies against platelet factor 4 (PF4)-polyanion complexes. We here report vaccine-induced isolated carotid arterial thrombosis. METHODS: Imaging and laboratory findings, treatment decisions and outcome of this case are presented. RESULTS: Eight days after having received the first dose of ChAdOx1 nCov-19 vaccine, a 31-year-old man was admitted to our stroke unit with acute headache, aphasia, and hemiparesis. D-dimers were slightly elevated, but platelet count and fibrinogen level were normal. MRI-confirmed mainstem occlusion of middle cerebral artery resolved within 1 hour after start of IV thrombolysis. A wall-adherent, non-occluding thrombus in the ipsilateral carotid bulb was identified as the source of embolism. Cardiac or paradoxical (venous) embolism was excluded. Screening for presence of heparin-induced thrombocytopenia-related antibodies was positive, and highly elevated serum IgG antibodies against PF4-polyanion complexes were subsequently proven. Treatment with aspirin and subcutaneous danaparoid, followed by phenprocoumon, led to thrombus shrinkage and dissolution within 19 days, and favorable clinical outcome. DISCUSSION: Vaccine history is important in patients not only with venous but also with arterial thromboembolic events. Vaccine-induced immune thrombosis of brain-supplying arteries may well be handled.
Authors: Danilo Toni; Alexander E Merkler; Manuela De Michele; Joshua Kahan; Irene Berto; Oscar G Schiavo; Marta Iacobucci Journal: Circ Res Date: 2022-04-14 Impact factor: 23.213
Authors: Diego López-Mena; Miguel García-Grimshaw; Sergio Saldivar-Dávila; Laura Elena Hernandez-Vanegas; María Del Mar Saniger-Alba; Alonso Gutiérrez-Romero; Roger Carrillo-Mezo; Hector Eduardo Valdez-Ruvalcaba; Vanessa Cano-Nigenda; Fernando Daniel Flores-Silva; Carlos Cantú-Brito; Ana María Santibañez-Copado; Jose-Luis Diaz-Ortega; Santa Elizabeth Ceballos-Liceaga; Luis Manuel Murillo-Bonilla; Ana Isabel Sepulveda-Núñez; Verónica García-Talavera; Eduardo Gonzalez-Guerra; Ricardo Cortes-Alcala; Hugo Lopez-Gatell; Guillermo Carbajal-Sandoval; Gustavo Reyes-Terán; Sergio Iván Valdés-Ferrer; Antonio Arauz Journal: Neurology Date: 2022-03-11 Impact factor: 11.800
Authors: Thomas Thiele; Karin Weisser; Linda Schönborn; Markus B Funk; Gabriele Weber; Andreas Greinacher; Brigitte Keller-Stanislawski Journal: Lancet Reg Health Eur Date: 2021-12-06